EF1g Gene Attenuation via DDD Regulatory System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current malaria vaccines face challenges due to the complex life cycle of Plasmodium, variable antigens, and imperfect experimental models, with existing attenuation methods like radiation-attenuated and drug-attenuated vaccines being unsafe or ineffective in providing consistent protection.
Innovation Solution
A regulatory system is developed to control the expression of the EF1g gene in Plasmodium using a dihydrofolate reductase degradation domain (DDD) regulatory element, allowing for conditional regulation of Plasmodium growth and attenuation, ensuring safety and efficacy by only expressing necessary genes when a regulatory drug is present.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiation-attenuated vaccine is used to attenuate Plasmodium, then the vaccine can be produced, but the attenuation is not controllable and safety cannot be guaranteed
Solution Approach 1:
The patent applies conditional gene expression systems (tet-on/off, inducible promoters) that allow dynamic control of Plasmodium gene expression. This enables the vaccine to be attenuated during production by suppressing essential gene expression, and then restored for safety before administration, making the attenuation process controllable and reversible rather than fixed and irreversible as in radiation-attenuated vaccines
Solution Approach 2:
The patent changes the physiological state of Plasmodium by controlling gene expression parameters through chemical inducers (doxycycline, tetracycline). By adjusting the presence or absence of these inducers, the expression level of essential genes can be precisely controlled, allowing safe attenuation during vaccine production while maintaining the ability to restore full functionality for safety verification
2Reliability
If drug-attenuated vaccine is used to attenuate Plasmodium, then the vaccine can be produced, but it may cause parasitemia and spread malaria
Solution Approach 1:
The patent extracts and removes the harmful effect of drug-attenuated vaccines by using genetic manipulation instead of chemical drugs to achieve attenuation. The essential genes are suppressed through RNA interference or conditional expression systems, eliminating the need for antimalarial drugs that cause parasitemia and potential malaria spread, while still achieving the desired attenuation effect
Solution Approach 2:
The patent introduces small interfering RNA (siRNA) or conditional gene expression systems as intermediaries to mediate the attenuation process. These intermediaries specifically target and suppress essential gene expression without requiring antimalarial drugs, thereby achieving safe attenuation without causing parasitemia or malaria spread that are associated with drug-based approaches
3Reliability
If essential genes of Plasmodium are knocked out to attenuate it, then the vaccine provides immunity, but the growth and survival of Plasmodium is affected
Solution Approach 1:
The patent uses conditional gene expression systems that allow dynamic control of essential gene expression. During vaccine production, gene expression is suppressed to achieve attenuation and stimulate immunity. Before vaccine administration, the expression is restored to ensure Plasmodium growth and survival, maintaining both immunity protection and parasite viability for safety
Solution Approach 2:
The patent implements periodic control of gene expression through inducible systems. The essential genes are periodically suppressed during vaccine manufacturing to achieve attenuation, then periodically restored before vaccine release and administration to ensure Plasmodium viability. This periodic on/off control allows the system to achieve both immunity induction and parasite survival at different stages
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system effectively controls Plasmodium growth and attenuation, providing a safe and effective means to prevent malaria by regulating the EF1g gene expression, thereby offering a promising strategy for malaria vaccine development.
Implementation Method 1
A regulatory system is developed to control the expression of the EF1g gene in Plasmodium using a dihydrofolate reductase degradation domain (DDD) regulatory element, allowing for conditional regulation of Plasmodium growth and attenuation
Data Source
AI summary
Disclosed are an attenuation system and the use thereof for attenuating plasmodia, specifically the use of an EF1g gene for attenuating plasmodia. The attenuation system regulates the expression or degradation of the EF1g gene by using a regulatory system, thereby controlling the growth of plasmodia and achieving the attenuation of plasmodia.